Videos

Elizabeth Plimack, MD discusses recent results from the phase 2 nivolumab and cabozantinib trial in nccRCC.

Dr. Motzer discusses the major challenges and mitigation strategies for managing high-grade adverse events with nccRCC regimens.

Dr. Motzer compares combination IO + TKIs to single agent ICI or TKI therapy regarding efficacy in nccRCC patients.

Abdullah M. Khan, MBBS, discusses the pivotal phase 3 KarMMa-3 trial of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, explores how CAR-T therapy may impact the future treatment landscape for R/R MM, including current unmet needs and clinical pearls for community oncologists treating patients with R/R MM.

Binod Dhakal, MD, shares clinical perspectives on using CAR-T therapy in R/R MM, highlighting the implications of the latest data for community oncologists and their patients.

Binod Dhakal, MD, discusses the current approach to sequencing CAR-T therapy for patients with R/R MM, including the impact of emerging bispecific antibodies and the potential role of CAR-T in earlier lines of therapy.

Binod Dhakal, MD, explores clinicians' safety concerns with using CAR-T therapy in R/R MM, including notable adverse events from recent clinical data and strategies for managing these events in practice.

Binod Dhakal, MD, discusses the latest results from the KarMMA-3 study, which investigated idecabtagene vicleucel (ide-cel) for patients with R/R MM, covering study design, patient population, and key takeaways.

Binod Dhakal, MD, reviews the latest results from the CARTITUDE-4 study, which evaluated ciltacabtagene autoleucel (cilta-cel) versus standard of care in patients with R/R MM, including study design, patient population, and key efficacy findings.

Binod Dhakal, MD, explores the role of CAR-T cell therapy in R/R MM, including an overview of the process, patient selection criteria, and identifying suitable candidates.

Binod Dhakal, MD, discusses the current standard of care for R/R MM, highlighting how treatment decision-making changes for patients who are refractory to lenalidomide and/or bortezomib.

Binod Dhakal, MD, provides a high-level overview of relapsed/refractory multiple myeloma (R/R MM), including the clinical hallmarks, risk factors, and patient stratification.

Ariel Lopez-Chavez, MD, discusses some of the research on evaluating PD-L1 therapy for patients with small cell lung cancer.

Brian Slomovitz, MD, MS, FACOG, discusses the potential use of tisotumab vedotin-tftv in combinations for the treatment of patients with second- or third-line recurrent or metastatic cervical cancer.

Adam D. Cohen, MD, discusses the different chimeric antigen receptor T-cell therapies used for multiple myeloma treatment and delves into their potential benefits and risks.

Following a discussion on zanubrutinib that highlighted clinical trial data, treatment practices, and adverse event considerations, the Oncology Brothers offer concluding thoughts.

Mazyar Shadman, MD, MPH, provides clinical insights on adverse events seen with zanubrutinib in patients with chronic lymphocytic leukemia.

A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Mazyar Shadman, MD, MPH, to discuss the ALPINE study looking at zanubrutinib vs ibrutinib in relapsed or refractory CLL.

Mazyar Shadman, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD; and Rahul Gosain, MD, to discuss the SEQUOIA trial investigating zanubrutinib vs bendamustine-rituximab in first-line CLL/SLL.

In closing the discussion, Dr Mascarenhas shares clinical pearls for community oncologists treating patients with myelofibrosis.

John Mascarenhas, MD, looks to the future of myelofibrosis treatment, noting present challenges and treatment strategies in development that may address those unmet needs.

Focusing on the safety profiles of JAK2 inhibitors, a myelofibrosis specialist discusses the adverse events encountered with pacritinib, ruxolitinib, and momelotinib.

John Mascarenhas, MD, reviews JAK2 inhibitor options for patients with myelofibrosis, including pacritinib, ruxolitinib, and momelotinib.

An expert on myelofibrosis discusses clinical studies investigating pacritinib, including data from the latest survival analysis of the PERSIST-2 clinical trial.

A hematologist-oncologist gives an overview of the treatment of myelofibrosis by defining the disease and highlighting biological pathways, therapeutic options, and factors that drive treatment selection.

John O. Mascarenhas, MD, presents the case of a 62-year-old man with myelofibrosis and provides clinical insights on treatment decisions.

Jennifer A. Woyach, MD, discusses how pirtobrutinib compares against other Bruton tyrosine kinase inhibitors and delves into the next steps for the agent in the CLL/SLL space.

Dr. Hammers discusses future management for advanced RCC, unmet needs, and emerging data being monitored.